PTGS2 and chronic kidney disease: Given the adverse effects associated with current COX-2 inhibitors, such as exacerbation of chronic kidney disease, gastrointestinal complications and increased cardiovascular risk, we sought a more suitable pharmaceutical that could both inhibit COX-2 and be employed in the treatment of wear debris-induced osteolysis.